SB27

pembrolizumab biosimilar · Samsung Bioepis Co., Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for SB27, covering 2025-11-17 to 2026-07-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer [Phase 3]

See pricing